Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 23364659)

1.

Remission induction in a case of refractory Behçet disease with alemtuzumab.

Perez-Pampin E, Campos-Franco J, Blanco J, Mera A.

J Clin Rheumatol. 2013 Mar;19(2):101-3. doi: 10.1097/RHU.0b013e318284735c. No abstract available.

PMID:
23364659
2.

Alemtuzumab induction in lung transplantation: time to move on?

Todd JL, Palmer SM.

Am J Transplant. 2014 Aug;14(8):1721-2. doi: 10.1111/ajt.12825. Epub 2014 Jul 10.

PMID:
25039475
3.

Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases.

Diamantopoulos AP, Hatemi G.

Rheumatology (Oxford). 2013 Oct;52(10):1923-4. doi: 10.1093/rheumatology/ket130. Epub 2013 Apr 4. No abstract available.

PMID:
23559575
4.

Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).

Braester A, Akria L, Suriu C, Sonkin V.

Acta Haematol. 2013;129(3):185-6. doi: 10.1159/000345254. Epub 2012 Dec 19. Review. No abstract available.

PMID:
23257842
5.

Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?

Fernandes IC, Gonçalves M, dos Anjos Teixeira M, Gonçalves C, Coutinho J, Selores M, Alves R, Lima M.

J Am Acad Dermatol. 2012 Nov;67(5):1083-5. doi: 10.1016/j.jaad.2012.05.010. No abstract available.

PMID:
23062898
6.

Peginesatide acetate, axitinib, and pertuzumab.

Hussar DA, Genco AT.

J Am Pharm Assoc (2003). 2012 Sep-Oct;52(5):716-9. Review. No abstract available.

PMID:
23023854
7.

Refractory neuro-Behçet treated by tocilizumab: a case report.

Urbaniak P, Hasler P, Kretzschmar S.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S73-5. Epub 2012 Sep 27.

PMID:
23020826
8.

Neurological complications of Behçet's syndrome.

Kidd D.

Curr Neurol Neurosci Rep. 2012 Dec;12(6):675-9. doi: 10.1007/s11910-012-0316-1. Review.

PMID:
23007835
9.

Gemtuzumab-induced orchitis in a patient with refractory acute promyelocytic leukaemia.

Jalil-ur-Rehman, Kelta M, Awad K, Beirouti BA, Nasser S, Aslam M.

J Coll Physicians Surg Pak. 2012 Sep;22(9):596-7. doi: 09.2012/JCPSP.596597.

PMID:
22980618
10.

Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia.

Reda G, Maura F, Gritti G, Gregorini A, Binda F, Guidotti F, Piciocchi A, Visco C, Rodeghiero F, Cortelezzi A.

Am J Hematol. 2012 Sep;87(9):936-7. doi: 10.1002/ajh.23268. Epub 2012 Jun 20.

PMID:
22718434
11.

[Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet disease].

Shimizu Y, Takeda T, Matsumoto R, Yoshida K, Nakajima J, Atarashi T, Yanagisawa H, Kikuchi K, Kikuchi H.

Nihon Shokakibyo Gakkai Zasshi. 2012 May;109(5):774-80. Japanese.

PMID:
22688103
12.

Cutaneous T-cell lymphoma's confounding nature.

Schmidt C.

J Natl Cancer Inst. 2012 Jun 6;104(11):806-8. doi: 10.1093/jnci/djs266. Epub 2012 Jun 6. No abstract available.

13.

Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.

Morgan RD, O'Callaghan JM, Knight SR, Morris PJ.

Transplantation. 2012 Jun 27;93(12):1179-88. doi: 10.1097/TP.0b013e318257ad41. Review.

PMID:
22660659
14.

Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.

Galeotti C, Boucheron A, Guillaume S, Koné-Paut I.

Mol Cancer Ther. 2012 Aug;11(8):1623-6. doi: 10.1158/1535-7163.MCT-11-0972. Epub 2012 May 25.

15.

Paraneoplastic pemphigus associated with chronic lymphocytic leukaemia: treatment with alemtuzumab.

Ekbäck M, Uggla B.

Leuk Res. 2012 Aug;36(8):e190-1. doi: 10.1016/j.leukres.2012.04.016. Epub 2012 May 11. No abstract available.

PMID:
22579369
16.

A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.

Paul RN, Alizadeh L, Ajayi OI, Karpurapu H, Ganesan C, Taddesse-Heath L, Aggarwal A.

Acta Haematol. 2012;127(4):235-43. doi: 10.1159/000336241. Epub 2012 Apr 13. Review.

PMID:
22517037
17.

Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.

Anderson AE, Lorenzi AR, Pratt A, Wooldridge T, Diboll J, Hilkens CM, Isaacs JD.

Rheumatology (Oxford). 2012 Aug;51(8):1397-406. doi: 10.1093/rheumatology/kes038. Epub 2012 Mar 24.

18.

Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.

Doubek M, Trbušek M, Malčíková J, Brychtová Y, Smardová J, Lochmanová J, Panovská A, Skuhrová Francová H, Mráz M, Tichý B, Sebejová L, Navrkalová V, Plevová K, Kuglík P, Mayer J, Pospíšilová S.

Leuk Lymphoma. 2012 Sep;53(9):1817-9. doi: 10.3109/10428194.2012.658794. Epub 2012 Mar 1. No abstract available.

PMID:
22263566
19.

Response to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging.

Syed FF, Bleeker JS, Glockner J, Pardanani A, Cooper LT Jr.

J Am Coll Cardiol. 2012 Jan 24;59(4):430. doi: 10.1016/j.jacc.2011.06.078. No abstract available.

20.

Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: clinical report of three patients.

Castelli R, Gritti G, Cannavò A, Moreo G, Conti G, Reda G, Cortelezzi A.

Immunopharmacol Immunotoxicol. 2012 Aug;34(4):717-20. doi: 10.3109/08923973.2011.644295. Epub 2012 Jan 2.

PMID:
22208918
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk